Target Price | $117.64 |
Price | $107.20 |
Potential | 9.74% |
Number of Estimates | 22 |
22 Analysts have issued a price target Gilead Sciences 2026 . The average Gilead Sciences target price is $117.64. This is 9.74% higher than the current stock price. The highest price target is $140.00 30.60% , the lowest is $93.00 13.25% . | |
A rating was issued by 30 analysts: 18 Analysts recommend Gilead Sciences to buy, 12 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Gilead Sciences stock has an average upside potential 2026 of 9.74% . Most analysts recommend the Gilead Sciences stock at Purchase. |
23 Analysts have issued a sales forecast Gilead Sciences 2025 . The average Gilead Sciences sales estimate is $28.7b . This is 0.15% lower than the revenue of the last 12 months(TTM). The highest sales forecast is $29.5b 2.49% , the lowest is $28.3b 1.57% .
This results in the following potential growth metrics:
2024 | $28.8b | 6.04% |
---|---|---|
2025 | $28.7b | 0.21% |
2026 | $29.8b | 3.89% |
2027 | $31.3b | 5.10% |
2028 | $33.1b | 5.51% |
2029 | $34.3b | 3.80% |
11 Analysts have issued an Gilead Sciences EBITDA forecast 2025. The average Gilead Sciences EBITDA estimate is $14.2b . This is 6.21% lower than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $15.9b 5.04% , the lowest is $12.9b 14.46% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $13.6b | 8.28% |
---|---|---|
2025 | $14.2b | 4.35% |
2026 | $15.0b | 5.90% |
2027 | $16.2b | 7.91% |
2028 | $18.1b | 11.56% |
2029 | $19.6b | 8.28% |
2024 | 47.28% | 2.12% |
---|---|---|
2025 | 49.44% | 4.57% |
2026 | 50.40% | 1.94% |
2027 | 51.75% | 2.68% |
2028 | 54.72% | 5.74% |
2029 | 57.08% | 4.31% |
11 Gilead Sciences Analysts have issued a net profit forecast 2025. The average Gilead Sciences net profit estimate is $7.5b . This is 26.15% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $8.6b 43.76% , the lowest is $7.1b 18.76% .
This results in the following potential growth metrics and future Net Margins:
2024 | $480m | 91.53% |
---|---|---|
2025 | $7.5b | 1,467.63% |
2026 | $8.8b | 16.89% |
2027 | $9.8b | 11.30% |
2028 | $10.6b | 8.71% |
2024 | 1.67% | 92.01% |
---|---|---|
2025 | 26.22% | 1,470.69% |
2026 | 29.50% | 12.51% |
2027 | 31.24% | 5.90% |
2028 | 32.19% | 3.04% |
11 Analysts have issued a Gilead Sciences forecast for earnings per share. The average Gilead Sciences EPS is $6.04 . This is 27.70% higher than earnings per share in the financial year 2024. The highest EPS forecast is $6.89 45.67% , the lowest is $5.69 20.30% .
This results in the following potential growth metrics and future valuations:
2024 | $0.38 | 91.56% |
---|---|---|
2025 | $6.04 | 1,489.47% |
2026 | $7.06 | 16.89% |
2027 | $7.86 | 11.33% |
2028 | $8.55 | 8.78% |
Current | 22.66 | 87.81% |
---|---|---|
2025 | 17.74 | 21.73% |
2026 | 15.17 | 14.49% |
2027 | 13.63 | 10.15% |
2028 | 12.54 | 8.00% |
Based on analysts' sales estimates for 2025, the Gilead Sciences stock is valued at an EV/Sales of 5.24 and an P/S ratio of 4.65 .
This results in the following potential growth metrics and future valuations:
Current | 5.23 | 32.41% |
---|---|---|
2025 | 5.24 | 0.21% |
2026 | 5.04 | 3.75% |
2027 | 4.80 | 4.85% |
2028 | 4.55 | 5.22% |
2029 | 4.38 | 3.66% |
Current | 4.64 | 44.69% |
---|---|---|
2025 | 4.65 | 0.14% |
2026 | 4.47 | 3.75% |
2027 | 4.26 | 4.85% |
2028 | 4.03 | 5.22% |
2029 | 3.89 | 3.66% |
Gilead Sciences...
Analyst | Rating | Action | Date |
---|---|---|---|
Needham |
Hold
➜
Hold
|
Unchanged | May 21 2025 |
Oppenheimer |
Outperform
➜
Outperform
|
Unchanged | Apr 25 2025 |
Needham |
Hold
➜
Hold
|
Unchanged | Apr 25 2025 |
Morgan Stanley |
Overweight
➜
Overweight
|
Unchanged | Apr 25 2025 |
JP Morgan |
Overweight
➜
Overweight
|
Unchanged | Mar 27 2025 |
Morgan Stanley |
Overweight
➜
Overweight
|
Unchanged | Mar 11 2025 |
B of A Securities |
Buy
➜
Buy
|
Unchanged | Mar 05 2025 |
Analyst Rating | Date |
---|---|
Unchanged
Needham:
Hold
➜
Hold
|
May 21 2025 |
Unchanged
Oppenheimer:
Outperform
➜
Outperform
|
Apr 25 2025 |
Unchanged
Needham:
Hold
➜
Hold
|
Apr 25 2025 |
Unchanged
Morgan Stanley:
Overweight
➜
Overweight
|
Apr 25 2025 |
Unchanged
JP Morgan:
Overweight
➜
Overweight
|
Mar 27 2025 |
Unchanged
Morgan Stanley:
Overweight
➜
Overweight
|
Mar 11 2025 |
Unchanged
B of A Securities:
Buy
➜
Buy
|
Mar 05 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.